Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1964 1
1965 2
1969 4
1970 2
1973 1
1974 2
1975 1
1976 4
1977 1
1978 1
1979 1
1980 2
1981 1
1982 4
1983 3
1984 2
1985 1
1986 6
1987 5
1989 1
1991 4
1992 2
1993 2
1994 2
1997 4
1998 9
1999 14
2000 9
2001 6
2002 11
2003 4
2004 6
2005 5
2006 9
2007 8
2008 9
2009 14
2010 17
2011 23
2012 20
2013 15
2014 11
2015 17
2016 10
2017 19
2018 14
2019 21
2020 24
2021 36
2022 17
2023 21
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

418 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Fischer K, et al. Among authors: tandon m. N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4. N Engl J Med. 2019. PMID: 31166681
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: tandon m. Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5. Lancet Oncol. 2020. PMID: 32888452 Clinical Trial.
ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer.
Baik JY, Liu Z, Jiao D, Kwon HJ, Yan J, Kadigamuwa C, Choe M, Lake R, Kruhlak M, Tandon M, Cai Z, Choksi S, Liu ZG. Baik JY, et al. Among authors: tandon m. Nat Commun. 2021 May 11;12(1):2666. doi: 10.1038/s41467-021-23004-3. Nat Commun. 2021. PMID: 33976222 Free PMC article.
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, Ching T, Tandon M, Fink AM, Tausch E, Schneider C, Ritgen M, Böttcher S, Kreuzer KA, Chyla B, Miles D, Wendtner CM, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: tandon m. J Clin Oncol. 2021 Dec 20;39(36):4049-4060. doi: 10.1200/JCO.21.01181. Epub 2021 Oct 28. J Clin Oncol. 2021. PMID: 34709929 Free PMC article. Clinical Trial.
Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.
Budhu A, Pehrsson EC, He A, Goyal L, Kelley RK, Dang H, Xie C, Monge C, Tandon M, Ma L, Revsine M, Kuhlman L, Zhang K, Baiev I, Lamm R, Patel K, Kleiner DE, Hewitt SM, Tran B, Shetty J, Wu X, Zhao Y, Shen TW, Choudhari S, Kriga Y, Ylaya K, Warner AC, Edmondson EF, Forgues M, Greten TF, Wang XW. Budhu A, et al. Among authors: tandon m. Cell Rep Med. 2023 Jun 20;4(6):101052. doi: 10.1016/j.xcrm.2023.101052. Epub 2023 May 23. Cell Rep Med. 2023. PMID: 37224815 Free PMC article.
Preschool bipolar disorder.
Luby JL, Tandon M, Belden A. Luby JL, et al. Among authors: tandon m. Child Adolesc Psychiatr Clin N Am. 2009 Apr;18(2):391-403, ix. doi: 10.1016/j.chc.2008.11.007. Child Adolesc Psychiatr Clin N Am. 2009. PMID: 19264269 Free PMC article. Review.
Materiovigilance Programme of India: Current status and way forward.
Saifuddin PK, Tandon M, Kalaiselvan V, Suroy B, Pattanshetti V, Prakash A, Medhi B. Saifuddin PK, et al. Among authors: tandon m. Indian J Pharmacol. 2022 May-Jun;54(3):221-225. doi: 10.4103/ijp.ijp_837_21. Indian J Pharmacol. 2022. PMID: 35848694 Free PMC article. Review.
418 results